On April 23, 2024 Be Biopharma, Inc. ("Be Bio"), a company pioneering the development of engineered B Cell Medicines (BCMs), reported that it will present at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, MD (Press release, Be Biopharma, APR 23, 2024, View Source [SID1234642243]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details regarding the Be Biopharma presentation at the conference are as follows:
Title: CRISPR/Cas9-based precision B cell gene engineering coupled with artificial intelligence-guided protein design produces active and sustained levels of tissue nonspecific alkaline phosphatase for the treatment of Hypophosphatasia
Presenter: Monika Musial-Siwek, Ph.D., Director, Protein Sciences, Be Biopharma
Date: May 10, 2024
Time: 12:00 PM ET
Session Title: Friday Posters: Musculo-Skeletal Diseases
Session Room: Exhibit Hall
Final Abstract Number: 1649
The abstract highlights Be Bio’s novel approach using engineered B-cell Medicines (BCMs) as a potential new treatment for Hypophosphatasia (HPP), a genetic disorder characterized by loss-of-function mutations in the ALPL gene which impairs the mineralization of bones. Researchers used CRISPR/Cas9 precision gene engineering and artificial intelligence-guided protein design to modify primary human B cells to produce tissue nonspecific alkaline phosphatase (ALP), an enzyme deficient in people living with HPP. The nonclinical data demonstrates the engineered BCM successfully produces active ALP , highlighting the therapeutic potential of the BCM platform as a novel treatment modality for HPP. BCMs have key attributes of plasma cells, including natural longevity, high levels of protein secretion, the ability to engraft without host preconditioning, and the ability to be re-dosed, making them an attractive platform for sustained supply of biologics.
For more information, please visit the conference website View Source
About Engineered B Cell Medicines – A New Class of Cellular Medicines
The B cell is a powerful cell that produces thousands of proteins per cell per second at constant levels, over decades. Precision genome editing can now be used to engineer B Cells that produce therapeutic proteins of interest, driving a new class of cellular medicines – Engineered B Cell Medicines (BCMs) – with the potential to be durable, allogeneic, redosable and administered without pre-conditioning. The promise of BCMs could transform therapeutic biologics with broad application — across protein classes, patient populations and therapeutic areas.